EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 31 / No 1 (Janvier 2015) Med Sci (Paris), 31 1 (2015) 60-67 References
Free Access
Issue
Med Sci (Paris)
Volume 31, Number 1, Janvier 2015
Page(s) 60 - 67
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153101014
Published online 06 February 2015
  1. Dalmau J, Tüzün E, Wu H, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007 ; 61 : 25–36. [CrossRef] [PubMed] [Google Scholar]
  2. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008 ; 7 : 1091–1098. [CrossRef] [PubMed] [Google Scholar]
  3. Zandi MS, Irani SR, Lang B, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011 ; 258 : 686–688. [CrossRef] [PubMed] [Google Scholar]
  4. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010 ; 167 : 261–280. [CrossRef] [PubMed] [Google Scholar]
  5. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011 ; 70 : 663–671. [CrossRef] [PubMed] [Google Scholar]
  6. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature 2009 ; 460 : 744–747. [PubMed] [Google Scholar]
  7. Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry 2014 ; 75 : 300–306. [CrossRef] [PubMed] [Google Scholar]
  8. Henneberg AE, Horter S, Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr Res 1994 ; 14 : 15–22. [CrossRef] [PubMed] [Google Scholar]
  9. Kantrowitz JT, Javitt DC. N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia ? Brain Res Bull 2010 ; 83 : 108–121. [CrossRef] [PubMed] [Google Scholar]
  10. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011 ; 10 : 63–74. [CrossRef] [PubMed] [Google Scholar]
  11. Tsutsui K, Kanbayashi T, Tanaka K, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012 ; 12 : 37. [CrossRef] [PubMed] [Google Scholar]
  12. Steiner J, Walter M, Glanz W, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: Specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013 ; 70 : 271–278. [CrossRef] [PubMed] [Google Scholar]
  13. Hammer C, Stepniak B, Schneider A, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 2014 ; 19 : 1143–1149. [CrossRef] [PubMed] [Google Scholar]
  14. Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010 ; 10 : 835–844. [CrossRef] [PubMed] [Google Scholar]
  15. Vincent A, Bien CG, Irani SR, et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011 ; 10 : 759–772. [CrossRef] [PubMed] [Google Scholar]
  16. Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the california encephalitis project. Clin Infect Dis 2012 ; 54 : 899–904. [CrossRef] [PubMed] [Google Scholar]
  17. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013 ; 12 : 157–165. [CrossRef] [PubMed] [Google Scholar]
  18. Kayser MS, Titulaer MJ, Gresa-Arribas N, et al. Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013 ; 70 : 1133–1139. [CrossRef] [PubMed] [Google Scholar]
  19. Gable MS, Gavali S, Radner A, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 2009 ; 28 : 1421–1429. [CrossRef] [PubMed] [Google Scholar]
  20. Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012 ; 72 : 902–911. [CrossRef] [PubMed] [Google Scholar]
  21. Moscato EH, Jain A, Peng X, et al. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 2010 ; 32 : 298–309. [CrossRef] [PubMed] [Google Scholar]
  22. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010 ; 133 : 1655–1667. [CrossRef] [PubMed] [Google Scholar]
  23. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014 ; 13 : 167–177. [CrossRef] [PubMed] [Google Scholar]
  24. Verhelst H, Verloo P, Dhondt K, et al. Anti-NMDA-receptor encephalitis in a 3 year old patient with chromosome 6p21.32 microdeletion including the HLA cluster. Eur J Paediatr Neurol 2011 ; 15 : 163–166. [CrossRef] [PubMed] [Google Scholar]
  25. Zhang Q, Tanaka K, Sun P, et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 2012 ; 45 : 610–615. [CrossRef] [PubMed] [Google Scholar]
  26. Pollak TA, McCormack R, Peakman M, et al. Prevalence of anti-N-methyl-d-aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med 2014 ; 44 : 2475–2487. [CrossRef] [PubMed] [Google Scholar]
  27. Masdeu JC, González-Pinto A, Matute C, et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am J Psychiatry 2012 ; 169 : 1120–1121. [CrossRef] [PubMed] [Google Scholar]
  28. Titulaer MJ, Dalmau J. Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia: a theory with unproven links. Mol Psychiatry 2014 ; 19 : 1054. [CrossRef] [Google Scholar]
  29. Najjar S, Pearlman DM, Alper K, et al. Neuroinflammation and psychiatric illness. J Neuroinflammation 2013 ; 10 : 43. [CrossRef] [PubMed] [Google Scholar]
  30. Creten C, van der Zwaan S, Blankespoor RJ, et al. Late onset autism and anti-NMDA-receptor encephalitis. Lancet 2011 ; 378 : 98. [CrossRef] [PubMed] [Google Scholar]
  31. Caplan JP, Binius T, Lennon VA, et al. Pseudopseudoseizures: conditions that may mimic psychogenic non-epileptic seizures. Psychosomatics 2011 ; 52 : 501–506. [CrossRef] [PubMed] [Google Scholar]
  32. Lebon S, Mayor-Dubois C, Popea I, et al. Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis mimicking a primary psychiatric disorder in an adolescent. J Child Neurol 2012 ; 27 : 1607–1610. [CrossRef] [PubMed] [Google Scholar]
  33. Choe C, Karamatskos E, Schattling B, et al. A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Res 2013 ; 208 : 194–196. [CrossRef] [PubMed] [Google Scholar]
  34. Busse S, Busse M, Brix B, et al. Seroprevalence of N-methyl-D-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients. Eur Arch Psychiatry Clin Neurosci 2014 ; 264 : 545–550. [CrossRef] [PubMed] [Google Scholar]
  35. Dickerson F, Stallings C, Vaughan C, et al. Antibodies to the glutamate receptor in mania. Bipolar Disord 2012 ; 14 : 547–553. [CrossRef] [PubMed] [Google Scholar]
  36. Lauvsnes MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 2012 ; 259 : 622–629. [CrossRef] [PubMed] [Google Scholar]
  37. Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain J Neurol 2012 ; 135 : 1606–1621. [CrossRef] [PubMed] [Google Scholar]
  38. Rhoads J, Guirgis H, McKnight C, Duchemin AM. Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schirophrenia. Schizophr Res 2011 ; 129 : 213–214. [CrossRef] [PubMed] [Google Scholar]
  39. Haussleiter IS, Emons B, Schaub M, et al. Investigation of antibodies against synaptic proteins in a cross-sectional cohort of psychotic pateints. Schizophr Res 2012 ; 140 : 258–259. [CrossRef] [PubMed] [Google Scholar]
  40. Gielen M.. Fonctionnement des récepteurs-canaux du glutamate. Med Sci (Paris) 2010 ; 26 : 65–72. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  41. Jacob L, Dauvilliers Y. La narcolepsie : une maladie auto-immune ? Med Sci (Paris) 2014 ; 30 : 1136–1143. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.